---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-22-000051"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:19:14.270257+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q1 2022: Revenue up 20.5% to $203.9M; operating loss of $4.0M vs income of $13.5M

## Summary
- Revenue $203.9M, up 20.5% YoY (21.8% constant currency).
- Vascular sales $122.8M (+37.7%); neuro $81.1M (+1.3%).
- Gross margin 62.5% vs 65.8% Q1 2021, impacted by labor/logistics costs.
- Operating loss $4.0M vs operating income $13.5M in Q1 2021.
- SG&A expense $110.9M, up from $79.8M, driving swing to loss.

## SEC filing metadata
- accession: 0001321732-22-000051
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173222000051/0001321732-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173222000051/pen-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-22-000051
- JSON: https://secwatch.observer/filing/0001321732-22-000051.json
- Plain text: https://secwatch.observer/filing/0001321732-22-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.